One of the best performing stocks in the market this year is at the center of an authentic Wall Street takeover war. Could it give your portfolio the lift it needs?
» Subscribe to CNBC: [ Ссылка ]
» Watch more Mad Money here: [ Ссылка ]
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Watch full episodes: [ Ссылка ]
Follow Mad Money on Twitter: [ Ссылка ]
Like Mad Money on Facebook: [ Ссылка ]
Follow Cramer on Twitter: [ Ссылка ]
Connect with CNBC News Online!
Get the latest news: [ Ссылка ]
Find CNBC News on Facebook: [ Ссылка ]
Follow CNBC News on Twitter: [ Ссылка ]
Follow CNBC News on Google+: [ Ссылка ]
Follow CNBC News on Instagram: [ Ссылка ]
Actavis CEO on Allergan | Mad Money | CNBC
Actavis CEO on Allergan | Mad Money | CNBC
Теги
mad money (tv program)Jim Cramerstock adviceJim Cramer interviewCEO interviewinterviewmad money interviewstock marketstock performancemarket newsstock picksActavis (Drug Manufacturer)Allergan (Business Operation)Forest Laboratories Inc. (Business Operation)IBSgrowthdriversCNBC (TV Network)businessnewsnewChief Executive Officer (Job Title)CEOorganic growthorganicdavid faber
